发明名称 Use of the genes in the Hog, Ras and cAMP pathway for treatment of fungal infection
摘要 Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of Cryptococcus neoformans, roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited. Therefore, an antifungal pharmaceutical composition including an inhibitor against the gene or protein encoded by the same can be used as an excellent combined antifungal agent which can reduce a conventional amount of an antifungal agent used and increase an efficiency.
申请公布号 US9017956(B2) 申请公布日期 2015.04.28
申请号 US201313862666 申请日期 2013.04.15
申请人 Nutrex Technology Co., Ltd. 发明人 Bahn Yong-Sun;Ko Young-Joon;Maeng Shin-Ae;Jung Kwang Woo;Kim Gyu Bum
分类号 C12Q1/00;A61K38/00;C08F210/18;A61K8/63;C12Q1/48;C07K14/37;C12Q1/18;C12N15/10 主分类号 C12Q1/00
代理机构 Swanson & Bratschun, L.L.C. 代理人 Swanson & Bratschun, L.L.C.
主权项 1. A method of screening a candidate agent for improving the fungal killing efficacy of an ergosterol-binding antifungal agent for Cryptococcus neoformans, comprising: contacting Ssk1 protein of Cryptococcus neoformans with the candidate agent; measuring whether the candidate agent inhibits an activity of Ssk1 protein; selecting a candidate agent which inhibits Ssk1 activity; determining whether fungal killing efficacy for Cryptococcus neoformans is improved for the ergosterol-binding antifungal agent when administered together with the selected candidate agent which inhibits Ssk1 activity, compared with sole treatment with the ergosterol-binding antifungal agent; and further selecting a candidate agent which is capable of improving the fungal killing efficacy of the ergosterol-binding antifungal agent.
地址 Seoul KR